Growth Metrics

Novartis Ag (NVS) Long-Term Deferred Tax (2016 - 2025)

Historic Long-Term Deferred Tax for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to $5.4 billion.

  • Novartis Ag's Long-Term Deferred Tax rose 2475.34% to $5.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.4 billion, marking a year-over-year increase of 2475.34%. This contributed to the annual value of $5.4 billion for FY2025, which is 2475.34% up from last year.
  • As of Q4 2025, Novartis Ag's Long-Term Deferred Tax stood at $5.4 billion, which was up 2475.34% from $5.6 billion recorded in Q3 2025.
  • Novartis Ag's 5-year Long-Term Deferred Tax high stood at $8.1 billion for Q2 2021, and its period low was $12.0 million during Q1 2021.
  • For the 5-year period, Novartis Ag's Long-Term Deferred Tax averaged around $4.1 billion, with its median value being $4.2 billion (2023).
  • Per our database at Business Quant, Novartis Ag's Long-Term Deferred Tax tumbled by 9741.38% in 2021 and then skyrocketed by 790196.08% in 2023.
  • Quarter analysis of 5 years shows Novartis Ag's Long-Term Deferred Tax stood at $3.7 billion in 2021, then dropped by 0.11% to $3.7 billion in 2022, then rose by 15.24% to $4.3 billion in 2023, then increased by 1.16% to $4.4 billion in 2024, then grew by 24.75% to $5.4 billion in 2025.
  • Its last three reported values are $5.4 billion in Q4 2025, $5.6 billion for Q3 2025, and $5.2 billion during Q2 2025.